← Back to Search

Other

Sleep Disturbance + Study Drug for Sleep Disorders (Sleep-MOR Trial)

Phase 2
Recruiting
Led By Michael T Smith, PhD
Research Sponsored by Johns Hopkins University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Must not have
BMI >35
Acute pain
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 90 minutes on day 3 of inpatient visit

Summary

This trial tests how different types of sleep problems affect the brain's response to a pain-relief drug and its potential for abuse. Healthy subjects will have their sleep patterns manipulated and then undergo brain scans and pain tests. The goal is to see if poor sleep makes pain drugs less effective or more likely to be abused.

Who is the study for?
This trial is for healthy adults aged 18-48 who sleep well (6.5 to 8.5 hours a night with good quality), don't smoke or use nicotine, and consume little caffeine. They must have had some exposure to opioids in the past but can't be overweight, have sleep disorders, metal implants unsafe for MRI, significant neurological diseases, recent serious medical issues or substance abuse history.
What is being tested?
The study tests how different types of sleep disturbances affect the brain's response to various drugs including stimulants, benzodiazepines, opioids, cannabinoids and pain relievers compared to placebo. It looks at drug effects on pain relief and potential for misuse under normal sleep conditions versus disrupted sleep.
What are the potential side effects?
Potential side effects depend on the specific medication given but may include drowsiness or alertness (for sedatives and stimulants respectively), addiction risk (opioids), changes in mood or appetite (cannabinoids) and typical over-the-counter medication risks like stomach upset.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My BMI is over 35.
Select...
I am currently experiencing severe pain.
Select...
I have not had significant health or mental health issues in the past 6 months, nor do I have a history of bipolar, psychotic disorders, or seizures.
Select...
I have had a head injury that made me unconscious for more than 3 minutes.
Select...
I have experienced chronic pain for a long time.
Select...
I do not have major brain or nerve diseases like lupus or MS.
Select...
I have been experiencing significant emotional or mental distress before being admitted.
Select...
I have been diagnosed with a sleep disorder.
Select...
I have been exposed to high levels of radiation before this study.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 90 minutes on day 3 of inpatient visit
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 90 minutes on day 3 of inpatient visit for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Drug Effects as assessed by the Visual Analog Scale
Percent change in receptor binding potential from PET scan
The monetary valuation in dollars of the study medication as assessed by the Drug or Money Multiple Choice Questionnaire
+1 more

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Sleep FragmentationExperimental Treatment2 Interventions
The Sleep fragmentation condition will be conducted on two consecutive nights. Subjects are provided an 8-hour sleep opportunity during which their sleep will be disturbed by microarousals that simulate sleep apnea.
Group II: Sleep Continuity DisruptionExperimental Treatment2 Interventions
The Sleep Continuity Disruption condition will be conducted on two consecutive nights. An 8-hour sleep opportunity period will be disturbed by several forced awakenings at random intervals during which no sleep is permitted.
Group III: Undisturbed SleepActive Control2 Interventions
An 8-hour period of undisturbed sleep is permitted on each night.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for sleep disorders include pharmacologic agents and behavioral interventions. Pharmacologic treatments often involve benzodiazepine receptor agonists, which enhance the effect of the neurotransmitter GABA, leading to sedative and hypnotic effects. These drugs can reduce sleep latency and increase total sleep time but may have side effects like daytime sleepiness and potential for dependence. Behavioral interventions, such as cognitive-behavioral therapy for insomnia (CBT-I), focus on changing sleep habits and thought patterns to improve sleep quality. Understanding these mechanisms is crucial for patients, as it helps tailor treatments to individual needs, potentially improving efficacy and minimizing side effects. In the context of receptor binding and pain inhibition, as studied in certain trials, these treatments may also impact pain perception and abuse liability, highlighting the importance of a comprehensive approach to managing sleep disorders.
Insomnia disorder: State of the science and challenges for the future.Insomnia.The effect of insomnia definitions, terminology, and classifications on clinical practice.

Find a Location

Who is running the clinical trial?

Johns Hopkins UniversityLead Sponsor
2,325 Previous Clinical Trials
14,874,738 Total Patients Enrolled
National Heart, Lung, and Blood Institute (NHLBI)NIH
3,931 Previous Clinical Trials
47,766,566 Total Patients Enrolled
Eric C Strain, MDStudy ChairJohns Hopkins University

Media Library

Within-Subject test of blinded study medication (Other) Clinical Trial Eligibility Overview. Trial Name: NCT04299490 — Phase 2
Sleep Disorders Research Study Groups: Sleep Continuity Disruption, Sleep Fragmentation, Undisturbed Sleep
Sleep Disorders Clinical Trial 2023: Within-Subject test of blinded study medication Highlights & Side Effects. Trial Name: NCT04299490 — Phase 2
Within-Subject test of blinded study medication (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04299490 — Phase 2
Sleep Disorders Patient Testimony for trial: Trial Name: NCT04299490 — Phase 2
~11 spots leftby Mar 2025